Astellas, Frequency Therapeutics Enter Alliance for Hearing Loss Treatment

Aims to develop and commercialize Frequency’s candidate, FX-322, for the treatment of sensorineural hearing loss

Astellas Pharma Inc. and Frequency Therapeutics, Inc. have entered into an exclusive license agreement to develop and commercialize Frequency’s regenerative therapeutic candidate, FX-322, for the treatment of sensorineural hearing loss, the most common type of hearing loss. Currently, there are no approved therapeutic options for sensorineural hearing loss.   Under the terms of the agreement, Astellas will be responsible for the development and commercialization of FX-322 outside of the U.S. a...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters